ghk-cu: GHK-Cu 50mg – High-Purity Laboratory-Verified Research Compound Cu peptide serum with 1% copper peptide for anti GHK-Cu 50mg | Purity Peptides

These compounds are intended strictly for scientific research, laboratory, or analytical use and are not approved for human consumption

Signs of Contamination to Watch For Cloudy solutions indicate possible bacterial contamination risks

included for metabolic research completeness

The histopathological assessment and scoring approach were performed in accordance with validated methods previously described in similar ischemia-reperfusion studies 10,14

(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)